401589-92-2 Usage
General Description
N-Cyclopropyl 3-nitrobenzenesulfonamide is a chemical compound that contains a cyclopropyl group attached to a nitrobenzenesulfonamide functional group. It is commonly used as a building block in the synthesis of pharmaceutical compounds and agrochemicals. The presence of the cyclopropyl group in the molecule gives it unique structural and physicochemical properties, making it useful for modifying the biological activity and pharmacokinetic properties of potential drug candidates. Additionally, the nitrobenzenesulfonamide moiety can also contribute to the compound's activity by acting as a pharmacophore or a bioisostere. Overall, the compound has potential applications in drug discovery and development as well as in the agrochemical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 401589-92-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,1,5,8 and 9 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 401589-92:
(8*4)+(7*0)+(6*1)+(5*5)+(4*8)+(3*9)+(2*9)+(1*2)=142
142 % 10 = 2
So 401589-92-2 is a valid CAS Registry Number.
InChI:InChI=1/C9H10N2O4S/c12-11(13)8-2-1-3-9(6-8)16(14,15)10-7-4-5-7/h1-3,6-7,10H,4-5H2
401589-92-2Relevant articles and documents
SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS
-
Page/Page column 105; 106, (2020/08/28)
Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c; or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
-
Page/Page column 141, (2016/04/26)
Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
